# Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate

> **NCT01996696** · PHASE2 · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 83 (actual)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01996696
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2020-11
- **Final completion:** 2020-11
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Results of interim analysis indicate no statistically significant difference in the primary objective between the two arms at baseline and 12 months of follow-up.
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01996696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01996696, "Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01996696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*